Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders

Risk factors for immunosuppression-associated infections in aquaporin-4 antibody mediated neuromyelitis optica spectrum disorders

Opis bibliograficzny
Główni autorzy:	Cheng, F, George, J, Rocha, J, Tackley, G, Revis, J, Waters, P, Elston, J, Palace, J, Jones, N, Leite, M
Format:	Conference item
Wydane:	2014

Podobne zapisy

Antibodies to aquaporin-1 are not present in neuromyelitis optica
od: Waters, P, i wsp.
Wydane: (2015)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies
od: Kitley, J, i wsp.
Wydane: (2013)

Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies.
od: Kitley, J, i wsp.
Wydane: (2013)

Features of neuromyelitis optica spectrum disorders and aquaporin-4 with myelin-oligodendrocyte glycoprotein antibodies-reply.
od: Kitley, J, i wsp.
Wydane: (2014)

Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Nour, M, i wsp.
Wydane: (2015)

NEUROMYELITIS OPTICA SPECTRUM AND RELATIONSHIP WITH AQUAPORIN-4 ANTIBODY DISEASE: THE OXFORD COHORT
od: Leite, M, i wsp.
Wydane: (2009)

Neuromyelitis Optica Spectrum Disorders With Aquaporin-4 and Myelin-Oligodendrocyte Glycoprotein Antibodies A Comparative Study
od: Kitley, J, i wsp.
Wydane: (2014)

Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study.
od: Kitley, J, i wsp.
Wydane: (2014)

Alternative antigen targets in aquaporin-4 antibodynegative neuromyelitis optica spectrum disorders
od: Kitley, J, i wsp.
Wydane: (2013)

Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders.
od: Kim, S, i wsp.
Wydane: (2013)

Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica
od: Waters, P, i wsp.
Wydane: (2016)

METHOTREXATE MAY BE AN ALTERNATIVE TO AZATHIOPRINE IN NEUROMYELITIS OPTICA WITH AQUAPORIN-4 ANTIBODIES
od: Kitley, J, i wsp.
Wydane: (2012)

Anti-aquaporin 4 antibody-positivity of Korean patients with neuromyelitis optica spectrum disorders
od: Min, J, i wsp.
Wydane: (2010)

Neuromyelitis optica relapses: race and rate, immunosuppression and impairment
od: Tackley, G, i wsp.
Wydane: (2016)

PREGNANCY OUTCOME IN AQUAPORIN-4 POSITIVE NEUROMYELITIS OPTICA SPECTRUM DISORDER: A MULTI-CENTER RETROSPECTIVE COHORT STUDY
od: Nour, M, i wsp.
Wydane: (2014)

The impact of neuromyelitis optica spectrum disorder on pregnancy outcome
od: Nour, M, i wsp.
Wydane: (2014)

Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder.
od: Pittock, S, i wsp.
Wydane: (2019)

Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica.
od: Paul, F, i wsp.
Wydane: (2007)

Aquaporin-4 Antibody Isoform Binding Specificity Does Not Explain Clinical Variations in Neuromyelitis Optica
od: Kitley, J, i wsp.
Wydane: (2013)

Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis.
od: Waters, P, i wsp.
Wydane: (2008)

NEUROMYELITIS OPTICA SPECTRUM DISORDER AND CMV RETINITIS: A CASE REPORT
od: George, J, i wsp.
Wydane: (2012)

Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers.
od: Palace, J, i wsp.
Wydane: (2010)

Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G
od: Kim, S-M, i wsp.
Wydane: (2016)

Condition-dependent generation of aquaporin-4 antibodies from circulating B cells in neuromyelitis optica
od: Wilson, R, i wsp.
Wydane: (2018)

Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G
od: Kim, S-M, i wsp.
Wydane: (2017)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan
od: Kitley, J, i wsp.
Wydane: (2012)

Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
od: Kitley, J, i wsp.
Wydane: (2012)

B cell and aquaporin‐4 antibody relationships with neuromyelitis optica spectrum disorder activity
od: Jeffrey L. Bennett, i wsp.
Wydane: (2024-10-01)

Magnetic resonance imaging in neuromyelitis optica.
od: Tackley, G, i wsp.
Wydane: (2014)

Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica.
od: Jarius, S, i wsp.
Wydane: (2008)

Pain in neuromyelitis optica spectrum disease: a cross-sectional study in an English cohort
od: Leonard, H, i wsp.
Wydane: (2012)

Advances on the diagnosis and treatment of aquaporin 4 antibody positive neuromyelitis optica spectrum disorders
od: XU Hong-jia, i wsp.
Wydane: (2024-05-01)

Neuromyelitis Optica Spectrum Disorder With Anti-Aquaporin-4 Antibody: Outcome Prediction Models
od: Liang Wang, i wsp.
Wydane: (2022-03-01)

The Importance of Aquaporin-4 Antibody Assays in Patients beyond the Diagnostic Criteria for Neuromyelitis Optica Spectrum Disorders
od: Sato, D, i wsp.
Wydane: (2013)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2014)

The role of imaging in diagnosing neuromyelitis optica spectrum disorder
od: Matthews, L, i wsp.
Wydane: (2013)

Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders
od: Damato, V, i wsp.
Wydane: (2022)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica
od: Jarius, S, i wsp.
Wydane: (2008)

Antibody to aquaporin-4 in the long-term course of neuromyelitis optica.
od: Jarius, S, i wsp.
Wydane: (2008)

Diagnosis of neuromyelitis optica (NMO) spectrum disorders: is MRI obsolete?
od: Downer, J, i wsp.
Wydane: (2012)